Loading clinical trials...
Loading clinical trials...
Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial
Conditions
Interventions
BI 695501
US-licensed Humira®
Locations
138
United States
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Rheumatology Associates
Birmingham, Alabama, United States
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Arizona Arthritis and Rheumatology Research, PLLC
Glendale, Arizona, United States
Arizona Arthritis and Rheumatology Research, PLLC
Mesa, Arizona, United States
Arizona Arthritis and Rheumatology Research, PLLC
Phoenix, Arizona, United States
Start Date
January 26, 2015
Primary Completion Date
March 3, 2016
Completion Date
October 18, 2016
Last Updated
January 19, 2018
NCT07017686
NCT05038553
NCT05790356
NCT03429426
NCT06028438
NCT06800157
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions